Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.
Valuation & Earnings
This table compares Zealand Pharma A/S and Recursion Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zealand Pharma A/S | $1.40 billion | 2.15 | $977.29 million | $6.03 | 6.96 |
| Recursion Pharmaceuticals | $74.68 million | 27.20 | -$644.76 million | ($1.04) | -3.65 |
Profitability
This table compares Zealand Pharma A/S and Recursion Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zealand Pharma A/S | 58.86% | 18.53% | 17.14% |
| Recursion Pharmaceuticals | -945.94% | -50.41% | -38.25% |
Insider & Institutional Ownership
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Zealand Pharma A/S has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Zealand Pharma A/S and Recursion Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zealand Pharma A/S | 0 | 9 | 1 | 1 | 2.27 |
| Recursion Pharmaceuticals | 1 | 2 | 2 | 0 | 2.20 |
Recursion Pharmaceuticals has a consensus price target of $8.06, indicating a potential upside of 112.38%. Given Recursion Pharmaceuticals’ higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Zealand Pharma A/S.
Summary
Zealand Pharma A/S beats Recursion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
